N Engl J Med
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Abstract
Background
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence.
Methods
In a double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy, to receive either adjuvant pembrolizumab (at a dose of 200 mg) or placebo intravenously once every 3 weeks for up to 17 cycles (approximately 1 year). The primary end point was disease-free survival according to the investigator's assessment. Overall survival was a key secondary end point. Safety was a secondary end point.
Results
A total of 496 patients were randomly assigned to receive pembrolizumab, and 498 to receive placebo. At the prespecified interim analysis, the median time from randomization to the data-cutoff date was 24.1 months. Pembrolizumab therapy was associated with significantly longer disease-free survival than placebo (disease-free survival at 24 months, 77.3% vs. 68.1%; hazard ratio for recurrence or death, 0.68; 95% confidence interval [CI], 0.53 to 0.87; P = 0.002 [two-sided]). The estimated percentage of patients who remained alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group (hazard ratio for death, 0.54; 95% CI, 0.30 to 0.96). Grade 3 or higher adverse events of any cause occurred in 32.4% of the patients who received pembrolizumab and in 17.7% of those who received placebo. No deaths related to pembrolizumab therapy occurred.
Conclusions
Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).
Related Questions
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
Mucinous tubular and spindle cell carcinoma (MTSCCC) of kidneys is a rare RCC variant which was first described in WHO 2024 updates of the classification of RCC (Moch et al., PMID 35853783). Most cases are diagnosed incidentally and typically have an indolent course with good long-term prognosis (Ku...
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
My preference in situations like this is to stabilize the renal function first. I am comfortable treating the patient with adjuvant pembrolizumab with a CrCl <30 mL/min but it should be stabilized first. That will make it easier to diagnose potential irAEs as compared to starting adjuvant treatment ...
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
For good-risk metastatic RCC patients, who are considered not a candidate for cytoreductive nephrectomy, systemic therapy with one of the IO/TKI combinations is indicated, taking into consideration the patient’s comorbidity and tolerance to the regimen. (For non-clear cell metastatic RCCs, systemic ...
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
I tend not to treat patients with resected/irradiated CNS lesion(s) if there is no disease elsewhere. Such patients were not included in the adjuvant pembro study, the activity of any systemic therapy for CNS disease is not well-established, and in general, I worry single agent pembro is undertreatm...
In metastatic/recurrent clear cell carcinoma with a solitary site of metastasis to the bone when, if ever, do you consider local therapy adequate and hold systemic therapy?
If I have a patient with a treated solitary metastatic site in RCC (bone or otherwise), I generally give local therapy and historically would not give systemic therapy. A point of discussion would be use of adjuvant pembro in this setting. While bone mets were not included in KEYNOTE-564 resected M1...
Do you offer adjuvant pembrolizumab post metachronous oligometastatic resection of RCC beyond the first year of diagnosis?
For patients with recurrence beyond 1 year of initial nephrectomy, I would not offer post metastasectomy pembrolizumab. Such patients would usually belong to the IMDC favorable risk category at the time of recurrence and could have a continued disease free interval post metastasectomy based on sever...
How would you approach a patient with resected renal cell carcinoma, collecting duct type with sarcomatoid and rhabdoid features?
Although sarcomatoid differentiation is more common in clear cell RCCs, it is also well described in other RCC subtypes, including collecting cell carcinoma. Some argue that collecting duct carcinoma is histologically and clinically closer to a urothelial carcinoma than an RCC subtype. Urothelial ca...
How do you manage patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy?
Patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy or M1 NED represent a challenging subset of patients given the heterogeneous nature of this subset and outcomes vary with the location and timing of metastatectomy.Prior VEGF-TKI studies after metastasectomy for ...